JCR Report

Overview

The report presents FY2019 consolidated net sales of 24,781 million yen, the eighth consecutive year of growth, while R&D expenditures reached 5,997 million yen. It highlights JCR's rare-disease pipeline, including JR-141 in Phase III in Japan and Phase II in Brazil, as well as the acquisition of ArmaGen in 2020. Sustainability coverage spans rare diseases, environment, society, and corporate governance, with FY2019 energy use of 3,784 kl and CO2 emissions of 426 tons.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2019-2020
Period: 1 April 2019 – 31 March 2020
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services